References:(
1.! Zucca! E,! Bertoni! F:! The( spectrum( of( MALT( lymphoma( at( different( sites:( biological( and(
therapeutic(relevance.!Blood(2016,!127(17):2082>2092.!
2.! Zucca!E,!Conconi!A,!Martinelli!G,!Bouabdallah!R,!Tucci!A,!Vitolo!U,!Martelli!M,!Pettengell!R,!Salles!
G,! Sebban! C( et( al:! Final( Results( of( the( IELSG?19( Randomized( Trial( of( Mucosa?Associated(
Lymphoid( Tissue( Lymphoma:( Improved( Event?Free( and( Progression?Free( Survival( With(
Rituximab( Plus( Chlorambucil( Versus( Either( Chlorambucil( or( Rituximab( Monotherapy.! J( Clin(
Oncol(2017,!35(17):1905>1912.!
3.! Swerdlow!SH,!Campo!E,!Pileri!SA,!Harris!NL,!Stein!H,!Siebert!R,!Advani!R,!Ghielmini!M,!Salles!GA,!
Zelenetz! AD( et( al:! The( 2016( revision( of( the( World( Health( Organization( classification( of(
lymphoid(neoplasms.!Blood(2016,!127(20):2375>2390.!
4.! Thieblemont!C,!Molina!T,!Davi!F:!Optimizing(therapy(for(nodal(marginal(zone(lymphoma.!Blood(
2016,!127(17):2064>2071.!
5.! Arcaini!L,!Rossi!D,!Paulli!M:!Splenic(marginal(zone(lymphoma:(from(genetics(to(management.!
Blood(2016,!127(17):2072>2081.!
6.! Alderuccio!JP,!Isrow!D,!Reis!IM,!Iyer!SG,!Meshman!JJ,!Zhao!W,!Vega!F,!Chapman!JR,!Markoe!AM,!
Lossos!IS:!Diagnostic(bone(marrow(biopsy(in(patients(with(stage(I(EMZL(treated(with(radiation(
therapy:(needed(or(not?!Blood(2020,!135(15):1299>1302.!
7.! Xochelli!A,!Oscier!D,!Stamatopoulos!K:!Clonal(B?cell(lymphocytosis(of(marginal(zone(origin.!Best(
Pract(Res(Clin(Haematol(2017,!30(1>2):77>83.!
8.! Zucca! E,! Arcaini! L,! Buske! C,! Johnson! PW,! Ponzoni! M,! Raderer! M,! Ricardi! U,! Salar! A,!
Stamatopoulos! K,! Thieblemont! C( et( al:! Marginal( zone( lymphomas:( ESMO( Clinical( Practice(
Guidelines(for(diagnosis,(treatment(and(follow?up.!Ann(Oncol(2020,!31(1):17>29.!
9.! Ayanambakkam!A,!Ibrahimi!S,!Bilal!K,!Cherry!MA:!Extranodal(Marginal(Zone(Lymphoma(of(the(
Central(Nervous(System.!Clin(Lymphoma(Myeloma(Leuk(2018,!18(1):34>37!e38.!
10.! Treglia! G,! Zucca! E,! Sadeghi! R,! Cavalli! F,! Giovanella! L,! Ceriani! L:! Detection( rate( of( fluorine?18?
fluorodeoxyglucose(positron(emission(tomography(in(patients(with(marginal(zone(lymphoma(
of(MALT(type:(a(meta?analysis.!Hematol(Oncol(2015,!33(3):113>124.!
11.! Vaxman!I,!Bernstine!H,!Kleinstern!G,!Hendin!N,!Shimony!S,!Domachevsky!L,!Gurion!R,!Groshar!D,!
Raanani!P,!Gafter>Gvili!A:!FDG(PET/CT(as(a(diagnostic(and(prognostic(tool(for(the(evaluation(of(
marginal(zone(lymphoma.!Hematol(Oncol(2019,!37(2):168>175.!
12.! Lowry!L,!Smith!P,!Qian!W,!Falk!S,!Benstead!K,!Illidge!T,!Linch!D,!Robinson!M,!Jack!A,!Hoskin!P:!
Reduced(dose(radiotherapy(for(local(control(in(non?Hodgkin(lymphoma:(a(randomised(phase(
III(trial.!Radiother(Oncol(2011,!100(1):86>92.!
13.! Hoskin! PJ,! Kirkwood! AA,! Popova! B,! Smith! P,! Robinson! M,! Gallop>Evans! E,! Coltart! S,! Illidge! T,!
Madhavan! K,! Brammer! C( et( al:! 4( Gy( versus( 24( Gy( radiotherapy( for( patients( with( indolent(
lymphoma( (FORT):( a( randomised( phase( 3( non?inferiority( trial.! Lancet( Oncol( 2014,! 15(4):457>
463.!
14.! Desai!A,!Joag!MG,!Lekakis!L,!Chapman!JR,!Vega!F,!Tibshirani!R,!Tse!D,!Markoe!A,!Lossos!IS:!Long?
term( course( of( patients( with( primary( ocular( adnexal( MALT( lymphoma:( a( large( single?
institution(cohort(study.!Blood(2017,!129(3):324>332.!
15.! Konig! L,! Dreyling! M,! Durig! J,! Engelhard! M,! Hohloch! K,! Viardot! A,! Witzens>Harig! M,! Kieser! M,!
Klapper! W,! Pott! C( et( al:! Therapy( of( nodal( Follicular( Lymphoma( (WHO( grade( 1/2)( in( clinical(
stage( I/II( using( response( adapted( Involved( Site( Radiotherapy( in( combination( with(
Obinutuzumab( (Gazyvaro)( ?( GAZAI( Trial( (GAZyvaro( and( response( adapted( Involved?site(
Radiotherapy):( a( study( protocol( for( a( single?arm,( non?randomized,( open,( national,( multi?
center(phase(II(trial.!Trials(2019,!20(1):544.!
16.! Yahalom! J,! Illidge! T,! Specht! L,! Hoppe! RT,! Li! YX,! Tsang! R,! Wirth! A,! International! Lymphoma!
Radiation! Oncology! G:! Modern( radiation( therapy( for( extranodal( lymphomas:( field( and( dose(
guidelines(from(the(International(Lymphoma(Radiation(Oncology(Group.!Int(J(Radiat(Oncol(Biol(
Phys(2015,!92(1):11>31.!
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES